Acute administration of an N-methyl-d-aspartate (NMDA) receptor antagonist used to model cortical inhibitory deficits (Homayoun and Moghaddam, 2007) also suppresses mPFC SST-IN activity and produces schizophrenia-like behavioral deficits (Ali et al., 2020). Here, SST is linked to schizophrenia.